secukinumab vs vunakizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriatic Arthritis

Shared mechanism: IL-17 · full Psoriatic Arthritis pipeline

secukinumab · Cosentyx

Marketed by Novartis

Approved in Psoriatic Arthritismonoclonal antibody
Reliable signal

NCT01392326 · Phase 3 · completed

In this large (n=606), randomized, quadruple-blind, placebo-controlled Phase 3 trial in active psoriatic arthritis, significantly more patients achieved an ACR20 response at week 24 on secukinumab 75 mg (50.5%) or 150 mg (50.0%) than on placebo (17.3%), a statistically significant difference for both doses (p<0.0001).

Next expected readout: October 2029 · NCT06751238 (registry estimate)

Reported efficacy

Proportion of Patients With Health Assessment Questionnaire - Disability Index (HAQ-DI) Response at Week 28 (Baseline, Week 28): HAQ-DI response (>=0.35-point improvement) at Week 28: secukinumab 57.1% (32/56) vs ustekinumab 27.0% (17/63); OR 3.647 (95% CI 1.601-8.311), p=0.002. (met)

Result source: NCT04632927

vunakizumab

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Psoriatic Arthritismonoclonal antibody
Partial signal

NCT05055934 · Phase 2 · completed

The study was randomized, quadruple-blind, placebo-controlled, and included 112 participants, using the clinical ACR20 improvement measure as its primary endpoint. The registry record gives no statistical test for the primary comparison; the key result shown reports it from the cited source.

Reported efficacy

Proportion of subjects achieving ACR 20 improvement at week 12: ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively (met)

Result source: NCT05055934

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointsecukinumabvunakizumab
ACR2051% vs 15.3%+35.7 vs placebo150 mg s.c. · wk 24 · n 100NCT01752634
17 other results
  • 42% vs 16.1% 150 mg · wk 24 · n 138 · Phase 3 · primary NCT01989468
  • 59.5% vs 27.4% 150 mg without load · wk 16 · n 222 · Phase 3 · primary NCT02404350
  • 55.5% vs 27.4% 150 mg with load · wk 16 · n 220 · Phase 3 · primary NCT02404350
  • 41.2% vs 18.4% 150 mg · wk 16 · n 114 · Phase 3 · primary NCT02294227
  • 39.8% vs 18.4% 150 mg · wk 16 · n 113 · Phase 3 · primary NCT02294227
  • 54% vs 15.3% 300 mg s.c. · wk 24 · n 100 · Phase 3 · primary NCT01752634
  • 48.2% vs 16.1% 300 mg · wk 24 · n 139 · Phase 3 · primary NCT01989468
  • 62.6% vs 27.4% 300 mg with load · wk 16 · n 222 · Phase 3 · primary NCT02404350
  • 29.3% vs 15.3% 75 mg s.c. · wk 24 · n 99 · Phase 3 · primary NCT01752634
  • 70% vs 28.6% 150 mg · wk 16 · n 20 · Phase 3 · primary NCT04711902
  • 67.4% vs 61.5% 300 mg s.c. · wk 52 · n 426 · Phase 3 · primary NCT02745080
  • 67.5% vs 31.3% 150 mg + 300 mg · wk 12 · n 83 · Phase 3 · secondary NCT02662985
  • 56.5% vs 18.5% 150 mg · wk 12 · n 157 · Phase 3 · secondary NCT02721966
  • 28.9% vs 19.3% 150 mg · wk 4 · n 114 · Phase 3 · secondary NCT02294227
  • 23% vs 19.3% 150 mg · wk 4 · n 113 · Phase 3 · secondary NCT02294227
  • 51.6% vs 18.5% 300 mg · wk 12 · n 164 · Phase 3 · secondary NCT02721966
  • 59.6% vs 29.0% 6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191 · Phase 3 · secondary NCT04209205
—Trial running · NCT06640257
ACR5031.4% vs 6.3%+25 vs placebo6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191NCT04209205
13 other results
  • 35% vs 7.1% 150 mg s.c. · wk 24 · n 100 · Phase 3 · secondary NCT01752634
  • 18.8% vs 8.8% 150 mg · wk 24 · n 138 · Phase 3 · secondary NCT01989468
  • 32% vs 8.1% 150 mg without load · wk 16 · n 222 · Phase 3 · secondary NCT02404350
  • 35.9% vs 8.1% 150 mg with load · wk 16 · n 220 · Phase 3 · secondary NCT02404350
  • 22.8% vs 6.1% 150 mg · wk 16 · n 114 · Phase 3 · secondary NCT02294227
  • 16.8% vs 6.1% 150 mg · wk 16 · n 113 · Phase 3 · secondary NCT02294227
  • 45.8% vs 8.4% 150 mg + 300 mg · wk 12 · n 83 · Phase 3 · secondary NCT02662985
  • 35% vs 7.1% 300 mg s.c. · wk 24 · n 100 · Phase 3 · secondary NCT01752634
  • 34.5% vs 8.8% 300 mg · wk 24 · n 139 · Phase 3 · secondary NCT01989468
  • 39.6% vs 8.1% 300 mg with load · wk 16 · n 222 · Phase 3 · secondary NCT02404350
  • 18.2% vs 7.1% 75 mg s.c. · wk 24 · n 99 · Phase 3 · secondary NCT01752634
  • 15% vs 4.8% 150 mg · wk 16 · n 20 · Phase 3 · secondary NCT04711902
  • 49% vs 44.8% 300 mg s.c. · wk 52 · n 426 · Phase 3 · secondary NCT02745080
—Trial running · NCT06640257
PASI 7548.3% vs 16.3%+32 vs placebo150 mg s.c. · wk 24 · n 58NCT01752634
10 other results
  • 50% vs 10.2% 150 mg · wk 24 · n 68 · Phase 3 · secondary NCT01989468
  • 58.1% vs 12.3% 150 mg without load · wk 16 · n 117 · Phase 3 · secondary NCT02404350
  • 60% vs 12.3% 150 mg with load · wk 16 · n 125 · Phase 3 · secondary NCT02404350
  • 52.7% vs 8.1% 150 mg · wk 16 · n 55 · Phase 3 · secondary NCT02294227
  • 50% vs 8.1% 150 mg · wk 16 · n 54 · Phase 3 · secondary NCT02294227
  • 63.4% vs 16.3% 300 mg s.c. · wk 24 · n 41 · Phase 3 · secondary NCT01752634
  • 46.8% vs 10.2% 300 mg · wk 24 · n 62 · Phase 3 · secondary NCT01989468
  • 70% vs 12.3% 300 mg with load · wk 16 · n 110 · Phase 3 · secondary NCT02404350
  • 28% vs 16.3% 75 mg s.c. · wk 24 · n 50 · Phase 3 · secondary NCT01752634
  • 60.7% vs 46% wk 28 · n 56 · Phase 3 · secondary NCT04632927
—Trial running · NCT06640257
Minimal disease activity22.4% vs 5.3%+17.2 vs placebo6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191NCT04209205
1 other result
  • 35.7% vs 22.2% wk 28 · n 56 · Phase 3 · secondary NCT04632927
—Trial running · NCT06640257
HAQ-DI, change-0.5 vs -0.3−0.2 vs placebo150 mg s.c. · wk 24 · n 95NCT01752634
12 other results
  • -0.3 vs -0.2 150 mg · wk 24 · n 138 · Phase 3 · secondary NCT01989468
  • -0.5 vs -0.2 150 mg without load · wk 16 · n 211 · Phase 3 · secondary NCT02404350
  • -0.4 vs -0.2 150 mg with load · wk 16 · n 210 · Phase 3 · secondary NCT02404350
  • -0.3 vs -0.2 150 mg · wk 12 · n 157 · Phase 3 · secondary NCT02721966
  • -0.6 vs -0.3 300 mg s.c. · wk 24 · n 95 · Phase 3 · secondary NCT01752634
  • -0.4 vs -0.2 300 mg · wk 24 · n 139 · Phase 3 · secondary NCT01989468
  • -0.6 vs -0.2 300 mg with load · wk 16 · n 211 · Phase 3 · secondary NCT02404350
  • -0.4 vs -0.2 300 mg · wk 12 · n 164 · Phase 3 · secondary NCT02721966
  • -0.3 vs -0.3 75 mg s.c. · wk 24 · n 89 · Phase 3 · secondary NCT01752634
  • -0.4 vs 0.1 6 mg/kg - 3 mg/kg i.v. · wk 16 · n 181 · Phase 3 · secondary NCT04209205
  • -0.3 vs 0.1 150 mg · wk 16 · n 19 · Phase 3 · secondary NCT04711902
  • -0.6 vs -0.6 300 mg s.c. · wk 52 · n 426 · Phase 3 · secondary NCT02745080
—Trial running · NCT06640257

ACR20

secukinumab
51% vs 15.3%+35.7 vs placebo150 mg s.c. · wk 24 · n 100NCT01752634
17 other results
  • 42% vs 16.1% 150 mg · wk 24 · n 138 · Phase 3 · primary NCT01989468
  • 59.5% vs 27.4% 150 mg without load · wk 16 · n 222 · Phase 3 · primary NCT02404350
  • 55.5% vs 27.4% 150 mg with load · wk 16 · n 220 · Phase 3 · primary NCT02404350
  • 41.2% vs 18.4% 150 mg · wk 16 · n 114 · Phase 3 · primary NCT02294227
  • 39.8% vs 18.4% 150 mg · wk 16 · n 113 · Phase 3 · primary NCT02294227
  • 54% vs 15.3% 300 mg s.c. · wk 24 · n 100 · Phase 3 · primary NCT01752634
  • 48.2% vs 16.1% 300 mg · wk 24 · n 139 · Phase 3 · primary NCT01989468
  • 62.6% vs 27.4% 300 mg with load · wk 16 · n 222 · Phase 3 · primary NCT02404350
  • 29.3% vs 15.3% 75 mg s.c. · wk 24 · n 99 · Phase 3 · primary NCT01752634
  • 70% vs 28.6% 150 mg · wk 16 · n 20 · Phase 3 · primary NCT04711902
  • 67.4% vs 61.5% 300 mg s.c. · wk 52 · n 426 · Phase 3 · primary NCT02745080
  • 67.5% vs 31.3% 150 mg + 300 mg · wk 12 · n 83 · Phase 3 · secondary NCT02662985
  • 56.5% vs 18.5% 150 mg · wk 12 · n 157 · Phase 3 · secondary NCT02721966
  • 28.9% vs 19.3% 150 mg · wk 4 · n 114 · Phase 3 · secondary NCT02294227
  • 23% vs 19.3% 150 mg · wk 4 · n 113 · Phase 3 · secondary NCT02294227
  • 51.6% vs 18.5% 300 mg · wk 12 · n 164 · Phase 3 · secondary NCT02721966
  • 59.6% vs 29.0% 6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191 · Phase 3 · secondary NCT04209205
vunakizumab
—Trial running · NCT06640257

ACR50

secukinumab
31.4% vs 6.3%+25 vs placebo6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191NCT04209205
13 other results
  • 35% vs 7.1% 150 mg s.c. · wk 24 · n 100 · Phase 3 · secondary NCT01752634
  • 18.8% vs 8.8% 150 mg · wk 24 · n 138 · Phase 3 · secondary NCT01989468
  • 32% vs 8.1% 150 mg without load · wk 16 · n 222 · Phase 3 · secondary NCT02404350
  • 35.9% vs 8.1% 150 mg with load · wk 16 · n 220 · Phase 3 · secondary NCT02404350
  • 22.8% vs 6.1% 150 mg · wk 16 · n 114 · Phase 3 · secondary NCT02294227
  • 16.8% vs 6.1% 150 mg · wk 16 · n 113 · Phase 3 · secondary NCT02294227
  • 45.8% vs 8.4% 150 mg + 300 mg · wk 12 · n 83 · Phase 3 · secondary NCT02662985
  • 35% vs 7.1% 300 mg s.c. · wk 24 · n 100 · Phase 3 · secondary NCT01752634
  • 34.5% vs 8.8% 300 mg · wk 24 · n 139 · Phase 3 · secondary NCT01989468
  • 39.6% vs 8.1% 300 mg with load · wk 16 · n 222 · Phase 3 · secondary NCT02404350
  • 18.2% vs 7.1% 75 mg s.c. · wk 24 · n 99 · Phase 3 · secondary NCT01752634
  • 15% vs 4.8% 150 mg · wk 16 · n 20 · Phase 3 · secondary NCT04711902
  • 49% vs 44.8% 300 mg s.c. · wk 52 · n 426 · Phase 3 · secondary NCT02745080
vunakizumab
—Trial running · NCT06640257

PASI 75

secukinumab
48.3% vs 16.3%+32 vs placebo150 mg s.c. · wk 24 · n 58NCT01752634
10 other results
  • 50% vs 10.2% 150 mg · wk 24 · n 68 · Phase 3 · secondary NCT01989468
  • 58.1% vs 12.3% 150 mg without load · wk 16 · n 117 · Phase 3 · secondary NCT02404350
  • 60% vs 12.3% 150 mg with load · wk 16 · n 125 · Phase 3 · secondary NCT02404350
  • 52.7% vs 8.1% 150 mg · wk 16 · n 55 · Phase 3 · secondary NCT02294227
  • 50% vs 8.1% 150 mg · wk 16 · n 54 · Phase 3 · secondary NCT02294227
  • 63.4% vs 16.3% 300 mg s.c. · wk 24 · n 41 · Phase 3 · secondary NCT01752634
  • 46.8% vs 10.2% 300 mg · wk 24 · n 62 · Phase 3 · secondary NCT01989468
  • 70% vs 12.3% 300 mg with load · wk 16 · n 110 · Phase 3 · secondary NCT02404350
  • 28% vs 16.3% 75 mg s.c. · wk 24 · n 50 · Phase 3 · secondary NCT01752634
  • 60.7% vs 46% wk 28 · n 56 · Phase 3 · secondary NCT04632927
vunakizumab
—Trial running · NCT06640257

Minimal disease activity

secukinumab
22.4% vs 5.3%+17.2 vs placebo6 mg/kg - 3 mg/kg i.v. · wk 16 · n 191NCT04209205
1 other result
  • 35.7% vs 22.2% wk 28 · n 56 · Phase 3 · secondary NCT04632927
vunakizumab
—Trial running · NCT06640257

HAQ-DI, change

secukinumab
-0.5 vs -0.3−0.2 vs placebo150 mg s.c. · wk 24 · n 95NCT01752634
12 other results
  • -0.3 vs -0.2 150 mg · wk 24 · n 138 · Phase 3 · secondary NCT01989468
  • -0.5 vs -0.2 150 mg without load · wk 16 · n 211 · Phase 3 · secondary NCT02404350
  • -0.4 vs -0.2 150 mg with load · wk 16 · n 210 · Phase 3 · secondary NCT02404350
  • -0.3 vs -0.2 150 mg · wk 12 · n 157 · Phase 3 · secondary NCT02721966
  • -0.6 vs -0.3 300 mg s.c. · wk 24 · n 95 · Phase 3 · secondary NCT01752634
  • -0.4 vs -0.2 300 mg · wk 24 · n 139 · Phase 3 · secondary NCT01989468
  • -0.6 vs -0.2 300 mg with load · wk 16 · n 211 · Phase 3 · secondary NCT02404350
  • -0.4 vs -0.2 300 mg · wk 12 · n 164 · Phase 3 · secondary NCT02721966
  • -0.3 vs -0.3 75 mg s.c. · wk 24 · n 89 · Phase 3 · secondary NCT01752634
  • -0.4 vs 0.1 6 mg/kg - 3 mg/kg i.v. · wk 16 · n 181 · Phase 3 · secondary NCT04209205
  • -0.3 vs 0.1 150 mg · wk 16 · n 19 · Phase 3 · secondary NCT04711902
  • -0.6 vs -0.6 300 mg s.c. · wk 52 · n 426 · Phase 3 · secondary NCT02745080
vunakizumab
—Trial running · NCT06640257
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

vunakizumab
ACR20 at week 12: 59.5% (vunakizumab 240 mg) and 47.4% (120 mg) vs 21.6% placebo; two-sided p = 0.0011 and p = 0.0206 respectively NCT05055934 · Phase 2 · design grade: moderate · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. secukinumab: 4 of 4 rows · vunakizumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricsecukinumab
Dropout rate
—150 mga
NCT01392326 · Phase 3
show 46 more results
—75 mg
NCT01392326 · Phase 3
5%150 mg s.c.
NCT01752634 · Phase 3
3%300 mg s.c.
NCT01752634 · Phase 3
6.1%75 mg s.c.
NCT01752634 · Phase 3
0%Secukinumab
NCT04632927 · Phase 3
—Secukinumab - Entire Study
NCT04632927 · Phase 3
—Secukinumab- On-Treatment
NCT04632927 · Phase 3
—
NCT03031782 · Phase 3
2.7%150 mg with load
NCT02404350 · Phase 3
6.8%150 mg without load
NCT02404350 · Phase 3
2.7%300 mg with load
NCT02404350 · Phase 3
—150 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
—150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
66.7%150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—300 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
47.4%75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—300 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—6 mg/kg - 3 mg/kg i.v
NCT04209205 · Phase 3 · registry result, not featured evidence
9.4%6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
1.2%150 mg + 300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
—150+300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02745080 · Phase 3 · registry result, not featured evidence
12.9%300 mg s.c.
NCT02745080 · Phase 3 · registry result, not featured evidence
10.8%
NCT02771210 · Phase 3 · registry result, not featured evidence
13.9%150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
17.4%300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
34.1%150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
26.6%300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
18.7%150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
18%150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
14.9%75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
15.6%75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
21.9%150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
22.1%150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT01169844 · Phase 2 · registry result, not featured evidence
10.7%2x 10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
—2x10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—150 mga
NCT01392326 · Phase 3
show 46 more results
—75 mg
NCT01392326 · Phase 3
0%150 mg s.c.
NCT01752634 · Phase 3
2%300 mg s.c.
NCT01752634 · Phase 3
3%75 mg s.c.
NCT01752634 · Phase 3
0%Secukinumab
NCT04632927 · Phase 3
—Secukinumab - Entire Study
NCT04632927 · Phase 3
—Secukinumab- On-Treatment
NCT04632927 · Phase 3
—
NCT03031782 · Phase 3
0.9%150 mg with load
NCT02404350 · Phase 3
0.9%150 mg without load
NCT02404350 · Phase 3
1.4%300 mg with load
NCT02404350 · Phase 3
—150 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
—150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
2.8%150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—300 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
0%75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—300 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—6 mg/kg - 3 mg/kg i.v
NCT04209205 · Phase 3 · registry result, not featured evidence
1%6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
0%150 mg + 300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
—150+300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02745080 · Phase 3 · registry result, not featured evidence
3.1%300 mg s.c.
NCT02745080 · Phase 3 · registry result, not featured evidence
4.9%
NCT02771210 · Phase 3 · registry result, not featured evidence
2.4%150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
2.4%300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
7.2%150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
10.8%300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
4%150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
3.7%150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
2.7%75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
4.8%75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
5.3%150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
7.1%150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
—3 mg/kg
NCT01169844 · Phase 2 · registry result, not featured evidence
—2x 10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
—2x10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
Serious AEs
17.3%150 mga
NCT01392326 · Phase 3
show 46 more results
11%75 mg
NCT01392326 · Phase 3
—150 mg s.c.
NCT01752634 · Phase 3
—300 mg s.c.
NCT01752634 · Phase 3
—75 mg s.c.
NCT01752634 · Phase 3
—Secukinumab
NCT04632927 · Phase 3
7.1%Secukinumab - Entire Study
NCT04632927 · Phase 3
5.4%Secukinumab- On-Treatment
NCT04632927 · Phase 3
14.6%
NCT03031782 · Phase 3
4.1%150 mg with load
NCT02404350 · Phase 3
2.7%150 mg without load
NCT02404350 · Phase 3
3.2%300 mg with load
NCT02404350 · Phase 3
3.9%150 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
7.9%300 mg
NCT02798211 · Phase 4 · registry result, not featured evidence
9.3%150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
0%300 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
0%75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03769168 · Phase 3 · registry result, not featured evidence
0%150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
—150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
4.8%300 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
5.9%6 mg/kg - 3 mg/kg i.v
NCT04209205 · Phase 3 · registry result, not featured evidence
—6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
—150 mg + 300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
5.6%150+300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence
8.7%300 mg
NCT02745080 · Phase 3 · registry result, not featured evidence
—300 mg s.c.
NCT02745080 · Phase 3 · registry result, not featured evidence
6.9%
NCT02771210 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
5.7%150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
5.6%300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
20.3%150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
6.1%300 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
16.4%75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—75 mg
NCT01892436 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
26.3%3 mg/kg
NCT01169844 · Phase 2 · registry result, not featured evidence
—2x 10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
14.3%2x10mg/kg
NCT00809614 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
150 mga
upper respiratory tract infection 20.3% (placebo 5.9%)
nasopharyngitis 18.3% (placebo 5.4%)
headache 8.5% (placebo 3.5%)
NCT01392326 · Phase 3
show 25 more results
75 mg
nasopharyngitis 20.9% (placebo 5.4%)
upper respiratory tract infection 17.8% (placebo 5.9%)
back pain 9.9% (placebo 1%)
NCT01392326 · Phase 3
nasopharyngitis 12.5%
covid-19 10.7%
arthralgia 8.9%
NCT04632927 · Phase 3
covid-19 10.7%
arthralgia 8.9%
diarrhoea 8.9%
NCT04632927 · Phase 3
nasopharyngitis 33.3% (placebo 28.9%)
diarrhoea 22.9% (placebo 15.8%)
nausea 22.9% (placebo 21.1%)
NCT03031782 · Phase 3
150 mg with load
upper respiratory tract infection 7.7% (placebo 3.3%)
viral upper respiratory tract infection 6.8% (placebo 8.7%)
pruritus 5% (placebo 1.2%)
NCT02404350 · Phase 3
150 mg without load
upper respiratory tract infection 6.3% (placebo 3.3%)
viral upper respiratory tract infection 5.9% (placebo 8.7%)
hypertension 4.1% (placebo 3%)
NCT02404350 · Phase 3
300 mg with load
viral upper respiratory tract infection 6.3% (placebo 8.7%)
diarrhoea 4.1% (placebo 6.6%)
bronchitis 3.6% (placebo 0.6%)
NCT02404350 · Phase 3
150 mg
back pain 7.8% (placebo 15.4%)
diarrhoea 6.8% (placebo 3.8%)
hypertension 5.8% (placebo 0%)
NCT02798211 · Phase 4 · registry result, not featured evidence
300 mg
upper respiratory tract infection 13.6% (placebo 1.9%)
diarrhoea 5.8% (placebo 3.8%)
back pain 5.2% (placebo 15.4%)
NCT02798211 · Phase 4 · registry result, not featured evidence
150 mg
covid-19 20.9%
nasopharyngitis 18.6%
pain in extremity 18.6%
NCT03769168 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 25%
arthralgia 18.8%
covid-19 18.8%
NCT03769168 · Phase 3 · registry result, not featured evidence
75 mg
arthralgia 21.1%
abdominal pain upper 15.8%
back pain 10.5%
NCT03769168 · Phase 3 · registry result, not featured evidence
150 mg
hyperlipidaemia 20% (placebo 38.1%)
hypercholesterolaemia 16.7% (placebo 0%)
hyperuricaemia 16.7% (placebo 9.5%)
NCT04711902 · Phase 3 · registry result, not featured evidence
300 mg
covid-19 23.8% (placebo 0%)
hyperuricaemia 19% (placebo 9.5%)
hyperlipidaemia 14.3% (placebo 38.1%)
NCT04711902 · Phase 3 · registry result, not featured evidence
6 mg/kg - 3 mg/kg i.v
covid-19 9.9% (placebo 3.7%)
urinary tract infection 4.5% (placebo 0.5%)
arthralgia 3.7% (placebo 1.6%)
NCT04209205 · Phase 3 · registry result, not featured evidence
150+300 mg
nasopharyngitis 11.8% (placebo 4.8%)
headache 8.1% (placebo 3.6%)
urinary tract infection 6.2% (placebo 3.6%)
NCT02662985 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 20.7%
upper respiratory tract infection 9.9%
headache 8.5%
NCT02745080 · Phase 3 · registry result, not featured evidence
nasopharyngitis 12.7%
diarrhoea 7.8%
arthralgia 6.9%
NCT02771210 · Phase 3 · registry result, not featured evidence
150 mg
nasopharyngitis 9% (placebo 6.6%)
upper respiratory tract infection 5.7% (placebo 3%)
pharyngitis 5.3% (placebo 3%)
NCT02721966 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 13.7% (placebo 6.6%)
diarrhoea 6.5% (placebo 2.4%)
upper respiratory tract infection 4.8% (placebo 3%)
NCT02721966 · Phase 3 · registry result, not featured evidence
150 mg
nasopharyngitis 21.4% (placebo 5.4%)
upper respiratory tract infection 19.2% (placebo 5.9%)
headache 8.9% (placebo 3.5%)
NCT01892436 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 8.5% (placebo 5.4%)
upper respiratory tract infection 6.1% (placebo 5.9%)
bronchitis 5.5% (placebo 3%)
NCT01892436 · Phase 3 · registry result, not featured evidence
75 mg
nasopharyngitis 24% (placebo 5.4%)
upper respiratory tract infection 21.2% (placebo 5.9%)
headache 10.6% (placebo 3.5%)
NCT01892436 · Phase 3 · registry result, not featured evidence
3 mg/kg
nasopharyngitis 36.8% (placebo 44.4%)
arthralgia 26.3% (placebo 22.2%)
oropharyngeal pain 26.3% (placebo 33.3%)
NCT01169844 · Phase 2 · registry result, not featured evidence
2x10mg/kg
nasopharyngitis 25% (placebo 35.7%)
headache 21.4% (placebo 7.1%)
dizziness 14.3% (placebo 0%)
NCT00809614 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

secukinumab

ACR20 51% (n=100) vs 15.3% (n=98) placebo @ 24wk150 mg s.c.
responder rate · % of participants
NCT01752634 · Phase 3 · converted to % from 51 Participants as posted
show 17 more results
59.5% (n=222) vs 27.4% (n=332) placebo @ 16wk150 mg without load
NCT02404350 · Phase 3
55.5% (n=220) vs 27.4% (n=332) placebo @ 16wk150 mg with load
NCT02404350 · Phase 3
70% (n=20) vs 28.6% (n=21) placebo @ 16wk*150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence · converted to % from 14 Participants as posted
67.5% (n=83) vs 31.3% (n=83) placebo @ 12wk*150 mg + 300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence · converted to % from 56 Participants as posted
56.5% (n=157) vs 18.5% (n=164) placebo @ 12wk150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
42% (n=138) vs 16.1% (n=137) placebo @ 24wk*150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence · converted to % from 58 Participants as posted
41.2% (n=114) vs 18.4% (n=114) placebo @ 16wk*150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence · converted to % from 47 Participants as posted
39.8% (n=113) vs 18.4% (n=114) placebo @ 16wk*150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence · converted to % from 45 Participants as posted
28.9% (n=114) vs 19.3% (n=114) placebo @ 4wk*150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence · converted to % from 33 Participants as posted
23% (n=113) vs 19.3% (n=114) placebo @ 4wk*150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence · converted to % from 26 Participants as posted
54% (n=100) vs 15.3% (n=98) placebo @ 24wk*300 mg s.c.
NCT01752634 · Phase 3 · converted to % from 54 Participants as posted
62.6% (n=222) vs 27.4% (n=332) placebo @ 16wk300 mg with load
NCT02404350 · Phase 3
67.4% (n=426) vs 61.5% (n=427) Adalimumab @ 52wk300 mg s.c.
NCT02745080 · Phase 3 · registry result, not featured evidence
51.6% (n=164) vs 18.5% (n=164) placebo @ 12wk300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
48.2% (n=139) vs 16.1% (n=137) placebo @ 24wk*300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence · converted to % from 67 Participants as posted
29.3% (n=99) vs 15.3% (n=98) placebo @ 24wk*75 mg s.c.
NCT01752634 · Phase 3 · converted to % from 29 Participants as posted
59.6% (n=191) vs 29.01% (n=190) placebo @ 16wk6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
PASI 75 48.3% (n=58) vs 16.3% (n=43) placebo @ 24wk150 mg s.c.
responder rate · % of participants
NCT01752634 · Phase 3 · converted to % from 28 Participants as posted
show 10 more results
58.1% (n=117) vs 12.3% (n=162) placebo @ 16wk*150 mg without load
NCT02404350 · Phase 3 · converted to % from 68 Participants as posted
60% (n=125) vs 12.3% (n=162) placebo @ 16wk*150 mg with load
NCT02404350 · Phase 3 · converted to % from 75 Participants as posted
50% (n=68) vs 10.2% (n=59) placebo @ 24wk*150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence · converted to % from 34 Participants as posted
52.7% (n=55) vs 8.1% (n=62) placebo @ 16wk*150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence · converted to % from 29 Participants as posted
50% (n=54) vs 8.1% (n=62) placebo @ 16wk*150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence · converted to % from 27 Participants as posted
63.4% (n=41) vs 16.3% (n=43) placebo @ 24wk*300 mg s.c.
NCT01752634 · Phase 3 · converted to % from 26 Participants as posted
70% (n=110) vs 12.3% (n=162) placebo @ 16wk*300 mg with load
NCT02404350 · Phase 3 · converted to % from 77 Participants as posted
46.8% (n=62) vs 10.2% (n=59) placebo @ 24wk*300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence · converted to % from 29 Participants as posted
28% (n=50) vs 16.3% (n=43) placebo @ 24wk*75 mg s.c.
NCT01752634 · Phase 3 · converted to % from 14 Participants as posted
60.7% (n=56) vs 46% (n=63) Ustekinumab @ 28wk*
NCT04632927 · Phase 3 · converted to % from 34 Participants as posted
PASI 90 32.8% (n=58) vs 9.3% (n=43) placebo @ 24wk150 mg s.c.
responder rate · % of participants
NCT01752634 · Phase 3 · converted to % from 19 Participants as posted
show 10 more results
31.6% (n=117) vs 9.3% (n=162) placebo @ 16wk*150 mg without load
NCT02404350 · Phase 3 · converted to % from 37 Participants as posted
36.8% (n=125) vs 9.3% (n=162) placebo @ 16wk*150 mg with load
NCT02404350 · Phase 3 · converted to % from 46 Participants as posted
36.8% (n=68) vs 6.8% (n=59) placebo @ 24wk*150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence · converted to % from 25 Participants as posted
48.8% (n=41) vs 9.3% (n=43) placebo @ 24wk*300 mg s.c.
NCT01752634 · Phase 3 · converted to % from 20 Participants as posted
53.6% (n=110) vs 9.3% (n=162) placebo @ 16wk*300 mg with load
NCT02404350 · Phase 3 · converted to % from 59 Participants as posted
65.4% (n=215) vs 43.2% (n=202) Adalimumab @ 52wk300 mg s.c.
NCT02745080 · Phase 3 · registry result, not featured evidence
33.9% (n=62) vs 6.8% (n=59) placebo @ 24wk*300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence · converted to % from 21 Participants as posted
12% (n=50) vs 9.3% (n=43) placebo @ 24wk*75 mg s.c.
NCT01752634 · Phase 3 · converted to % from 6 Participants as posted
47.85% (n=49) vs 6.46% (n=7) placebo @ 16wk6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
48.2% (n=56) vs 39.7% (n=63) Ustekinumab @ 28wk*
NCT04632927 · Phase 3 · converted to % from 27 Participants as posted
DAS28-CRP -1.58 vs -0.96 placebo score @ 24wk150 mg s.c.
absolute change · score
NCT01752634 · Phase 3
show 10 more results
-1.29 vs -0.63 placebo score @ 16wk150 mg without load
NCT02404350 · Phase 3
-1.29 vs -0.63 placebo score @ 16wk150 mg with load
NCT02404350 · Phase 3
-1.47 vs -0.37 placebo score @ 16wk150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
-1.24 vs -0.64 placebo score @ 24wk150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
-0.98 vs -0.21 placebo score @ 16wk150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
-0.84 vs -0.21 placebo score @ 16wk150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence
-1.61 vs -0.96 placebo score @ 24wk300 mg s.c.
NCT01752634 · Phase 3
-1.49 vs -0.63 placebo score @ 16wk300 mg with load
NCT02404350 · Phase 3
-1.56 vs -0.64 placebo score @ 24wk300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
-1.12 vs -0.96 placebo score @ 24wk75 mg s.c.
NCT01752634 · Phase 3
SF-36 Physical Component 6.39 vs 1.95 placebo score @ 24wk150 mg s.c.
absolute change · score
NCT01752634 · Phase 3
show 2 more results
7.25 vs 1.95 placebo score @ 24wk300 mg s.c.
NCT01752634 · Phase 3
4.38 vs 1.95 placebo score @ 24wk75 mg s.c.
NCT01752634 · Phase 3
HAQ-DI -0.48 vs -0.31 placebo score @ 24wk150 mg s.c.
absolute change · score
NCT01752634 · Phase 3
show 12 more results
-0.45 vs -0.21 placebo score @ 16wk150 mg without load
NCT02404350 · Phase 3
-0.44 vs -0.21 placebo score @ 16wk150 mg with load
NCT02404350 · Phase 3
-0.31 vs 0.09 placebo score @ 16wk150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence
-0.33 vs -0.155 placebo score @ 12wk150 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
-0.27 vs -0.17 placebo score @ 24wk150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
-0.56 vs -0.31 placebo score @ 24wk300 mg s.c.
NCT01752634 · Phase 3
-0.55 vs -0.21 placebo score @ 16wk300 mg with load
NCT02404350 · Phase 3
-0.58 vs -0.56 Adalimumab score @ 52wk300 mg s.c.
NCT02745080 · Phase 3 · registry result, not featured evidence
-0.389 vs -0.155 placebo score @ 12wk300 mg
NCT02721966 · Phase 3 · registry result, not featured evidence
-0.38 vs -0.17 placebo score @ 24wk300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence
-0.32 vs -0.31 placebo score @ 24wk75 mg s.c.
NCT01752634 · Phase 3
-0.39 vs 0.15 placebo score @ 16wk6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
ACR50 35% (n=100) vs 7.1% (n=98) placebo @ 24wk150 mg s.c.
responder rate · % of participants
NCT01752634 · Phase 3 · converted to % from 35 Participants as posted
show 13 more results
32% (n=222) vs 8.1% (n=332) placebo @ 16wk*150 mg without load
NCT02404350 · Phase 3 · converted to % from 71 Participants as posted
35.9% (n=220) vs 8.1% (n=332) placebo @ 16wk*150 mg with load
NCT02404350 · Phase 3 · converted to % from 79 Participants as posted
15% (n=20) vs 4.8% (n=21) placebo @ 16wk*150 mg
NCT04711902 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted
45.8% (n=83) vs 8.4% (n=83) placebo @ 12wk*150 mg + 300 mg
NCT02662985 · Phase 3 · registry result, not featured evidence · converted to % from 38 Participants as posted
18.8% (n=138) vs 8.8% (n=137) placebo @ 24wk*150 mg
NCT01989468 · Phase 3 · registry result, not featured evidence · converted to % from 26 Participants as posted
22.8% (n=114) vs 6.1% (n=114) placebo @ 16wk*150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence · converted to % from 26 Participants as posted
16.8% (n=113) vs 6.1% (n=114) placebo @ 16wk*150 mg
NCT02294227 · Phase 3 · registry result, not featured evidence · converted to % from 19 Participants as posted
35% (n=100) vs 7.1% (n=98) placebo @ 24wk*300 mg s.c.
NCT01752634 · Phase 3 · converted to % from 35 Participants as posted
39.6% (n=222) vs 8.1% (n=332) placebo @ 16wk*300 mg with load
NCT02404350 · Phase 3 · converted to % from 88 Participants as posted
49% (n=426) vs 44.8% (n=427) Adalimumab @ 52wk300 mg s.c.
NCT02745080 · Phase 3 · registry result, not featured evidence
34.5% (n=139) vs 8.8% (n=137) placebo @ 24wk*300 mg
NCT01989468 · Phase 3 · registry result, not featured evidence · converted to % from 48 Participants as posted
18.2% (n=99) vs 7.1% (n=98) placebo @ 24wk*75 mg s.c.
NCT01752634 · Phase 3 · converted to % from 18 Participants as posted
31.35% (n=191) vs 6.33% (n=190) placebo @ 16wk6 mg/kg - 3 mg/kg i.v.
NCT04209205 · Phase 3 · registry result, not featured evidence
HAQ-DI 57.1% (n=56) vs 27% (n=63) Ustekinumab @ 28wk
responder rate · % of participants
NCT04632927 · Phase 3 · converted to % from 32 Participants as posted
Pain VAS -27.1 vs -16.4 Ustekinumab score @ 28wk
absolute change · score
NCT04632927 · Phase 3
TJC -9.6 vs -7.6 Ustekinumab score @ 28wk
absolute change · score
NCT04632927 · Phase 3
Swollen Joint Count -6.8 vs -5.3 Ustekinumab score @ 28wk
absolute change · score
NCT04632927 · Phase 3
PASI 100 37.5% (n=56) vs 27% (n=63) Ustekinumab @ 28wk
responder rate · % of participants
NCT04632927 · Phase 3 · converted to % from 21 Participants as posted

+ 98 further endpoints in the CSV export.

Psoriasis

Shared mechanism: IL-17 · full Psoriasis pipeline

secukinumab · Cosentyx

Marketed by Novartis

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT01358578 · Phase 3 · completed

This was a large, randomized, quadruple-blind trial with both placebo and active etanercept comparator groups, enrolling 1,306 participants. The clinical primary endpoints at week 12 were met in the favorable direction based on the reported counts: PASI 75 and IGA 0/1 responses were achieved by large majorities of secukinumab-treated participants compared with very few placebo-treated participants, although formal statistical analyses are not posted in the registry.

Next expected readout: December 2027 · NCT04239859 (registry estimate)

Reported efficacy

Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks); Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure:IGA (Investigator's Global Assessment) Mod 2011 With a 0 or 1 Response at Week 12 (12 wks): Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks): AIN457 150mg 219/327 (67.0%) | AIN457 300mg 249/323 (77.1%) vs Placebo 16/324 (4.9%) (met)

Result source: NCT01358578

vunakizumab

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in Psoriasismonoclonal antibody
Reliable signal

NCT04839016 · Phase 3 · status unknown

This randomized, double-blind, placebo-controlled Phase 3 trial randomized 690 patients with moderate-to-severe plaque psoriasis 2:1 to vunakizumab 240 mg or placebo. The co-primary endpoints were PASI 90 and sPGA 0/1 at week 12. PASI 90 was reached by 76.8% of patients on vunakizumab and 0.9% on placebo, and sPGA 0/1 by 71.8% and 0.4% (both two-sided P < .0001), so both co-primary endpoints were met. The registry record still shows its 2021 estimated enrollment of 660 and has no posted results; the figures come from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025).

Caveat: this result is taken from the peer-reviewed paper (Yan et al., J Am Acad Dermatol 2025, PMID 39332633); the ClinicalTrials.gov record (status unknown) has no posted results.

Next expected readout: March 2027 · NCT06779097 (registry estimate)

Reported efficacy

Percentage of subjects who achieve at least 90% improvement in PASI score (PASI 90) at Week 12; sPGA of 0 or 1 response at Week 12: Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025). (met)

Result source: NCT04839016

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointsecukinumabvunakizumab
PASI 7577.1% vs 4.9%+72.2 vs placebo300mg · wk 12 · n 323NCT01358578
27 other results
  • 81.6% vs 4.5% 300 mg · wk 12 · n 245 · Phase 3 · primary NCT01365455
  • 93.4% vs 4.4% 300 mg · wk 12 · n 272 · Phase 3 · primary NCT03066609
  • 67% vs 4.9% 150mg · wk 12 · n 327 · Phase 3 · primary NCT01358578
  • 71.6% vs 4.5% 150 mg · wk 12 · n 243 · Phase 3 · primary NCT01365455
  • 75.9% vs 0% 300 mg · wk 12 · n 58 · Phase 3 · primary NCT01555125
  • 82.4% vs 4.4% 150 mg · wk 12 · n 136 · Phase 3 · primary NCT03066609
  • 95.1% vs 10% 300 mg · wk 12 · n 41 · Phase 3 · primary NCT03589885
  • 69.5% vs 0% 150 mg · wk 12 · n 59 · Phase 3 · primary NCT01555125
  • 88.9% vs 1.4% 2 mL PFS · wk 12 · n 72 · Phase 3 · primary NCT02748863
  • 80% vs 14.6% low dose · wk 12 · n 40 · Phase 3 · primary NCT02471144
  • 77.5% vs 14.6% high dose · wk 12 · n 40 · Phase 3 · primary NCT02471144
  • 64.7% vs 2% wk 12 · n 51 · Phase 3 · secondary NCT02267135
  • 92% vs 79.9% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 77.1% vs 44% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 88% vs 74.1% 300 mg · wk 12 · n 550 · Phase 3 · secondary NCT02826603
  • 40.2% vs 16.3% 300 mg · wk 4 · n 550 · Phase 3 · secondary NCT02826603
  • 49.7% vs 20.6% 300 mg · wk 4 · n 334 · Phase 3 · secondary NCT02074982
  • 67% vs 44% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578
  • 88.6% vs 27.4% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 87.6% vs 21.1% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 80% vs 8.4% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 69.5% vs 2.1% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 47.6% vs 1.1% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 24.8% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 5.7% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 84.8% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701
—Trial running · NCT06833307
PASI 9079% vs 57.3%vs Ustekinumab300 mg · wk 16 · n 334NCT02074982
23 other results
  • 66.5% vs 48% 300 mg · wk 12 · n 550 · Phase 3 · primary NCT02826603
  • 54.2% vs 1.5% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 59.2% vs 1.2% 300 mg · wk 12 · n 245 · Phase 3 · secondary NCT01365455
  • 77.2% vs 1.5% 300 mg · wk 12 · n 272 · Phase 3 · secondary NCT03066609
  • 41.9% vs 1.5% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578
  • 39.1% vs 1.2% 150 mg · wk 12 · n 243 · Phase 3 · secondary NCT01365455
  • 62.5% vs 1.5% 150 mg · wk 12 · n 136 · Phase 3 · secondary NCT03066609
  • 75.6% vs 5% 300 mg · wk 12 · n 41 · Phase 3 · secondary NCT03589885
  • 47.1% vs 0% wk 12 · n 51 · Phase 3 · secondary NCT02267135
  • 66.7% vs 1.4% 2 mL PFS · wk 12 · n 72 · Phase 3 · secondary NCT02748863
  • 72.5% vs 2.4% low dose · wk 12 · n 40 · Phase 3 · secondary NCT02471144
  • 67.5% vs 2.4% high dose · wk 12 · n 40 · Phase 3 · secondary NCT02471144
  • 76.9% vs 54.2% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 68.6% vs 8.4% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 63.8% vs 2.1% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 46.7% vs 1.1% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 32.4% vs 0% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 17.1% vs 0% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 2.9% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 1.9% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 53.7% vs 0% 300 mg · wk 12 · n 54 · Phase 4 · primary NCT03055494
  • 73.9% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701
—Trial running · NCT06833307
PASI 10023.5% vs 0%+23.5 vs placebowk 12 · n 51NCT02267135
13 other results
  • 38.9% vs 0% 2 mL PFS · wk 12 · n 72 · Phase 3 · secondary NCT02748863
  • 36.6% vs 0% 2 x 1 mL PFS · wk 12 · n 71 · Phase 3 · secondary NCT02748863
  • 45.5% vs 26.6% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 38.2% vs 20.1% 300 mg · wk 12 · n 550 · Phase 3 · secondary NCT02826603
  • 37.1% vs 0% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 28.6% vs 0% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 15.2% vs 0% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 7.6% vs 0% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 3.8% vs 0% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 37% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701
—Trial running · NCT06833307
sPGA 0/162.5% vs 2.8%+59.7 vs placebo300mg · wk 12 · n 323NCT01358578
3 other results
  • 51.1% vs 2.8% 150mg · wk 12 · n 327 · Phase 3 · primary NCT01358578
  • 62.5% vs 27.2% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 51.1% vs 27.2% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578
—Trial running · NCT06833307
DLQI, change-13.2 vs -2.0−11.2 vs placebo300 mg · wk 12 · n 41NCT03589885
1 other result
  • -9.4 vs -0.5 wk 12 · n 46 · Phase 4 · secondary NCT02690701
—Trial running · NCT06833307

PASI 75

secukinumab
77.1% vs 4.9%+72.2 vs placebo300mg · wk 12 · n 323NCT01358578
27 other results
  • 81.6% vs 4.5% 300 mg · wk 12 · n 245 · Phase 3 · primary NCT01365455
  • 93.4% vs 4.4% 300 mg · wk 12 · n 272 · Phase 3 · primary NCT03066609
  • 67% vs 4.9% 150mg · wk 12 · n 327 · Phase 3 · primary NCT01358578
  • 71.6% vs 4.5% 150 mg · wk 12 · n 243 · Phase 3 · primary NCT01365455
  • 75.9% vs 0% 300 mg · wk 12 · n 58 · Phase 3 · primary NCT01555125
  • 82.4% vs 4.4% 150 mg · wk 12 · n 136 · Phase 3 · primary NCT03066609
  • 95.1% vs 10% 300 mg · wk 12 · n 41 · Phase 3 · primary NCT03589885
  • 69.5% vs 0% 150 mg · wk 12 · n 59 · Phase 3 · primary NCT01555125
  • 88.9% vs 1.4% 2 mL PFS · wk 12 · n 72 · Phase 3 · primary NCT02748863
  • 80% vs 14.6% low dose · wk 12 · n 40 · Phase 3 · primary NCT02471144
  • 77.5% vs 14.6% high dose · wk 12 · n 40 · Phase 3 · primary NCT02471144
  • 64.7% vs 2% wk 12 · n 51 · Phase 3 · secondary NCT02267135
  • 92% vs 79.9% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 77.1% vs 44% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 88% vs 74.1% 300 mg · wk 12 · n 550 · Phase 3 · secondary NCT02826603
  • 40.2% vs 16.3% 300 mg · wk 4 · n 550 · Phase 3 · secondary NCT02826603
  • 49.7% vs 20.6% 300 mg · wk 4 · n 334 · Phase 3 · secondary NCT02074982
  • 67% vs 44% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578
  • 88.6% vs 27.4% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 87.6% vs 21.1% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 80% vs 8.4% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 69.5% vs 2.1% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 47.6% vs 1.1% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 24.8% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 5.7% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 84.8% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701
vunakizumab
—Trial running · NCT06833307

PASI 90

secukinumab
79% vs 57.3%vs Ustekinumab300 mg · wk 16 · n 334NCT02074982
23 other results
  • 66.5% vs 48% 300 mg · wk 12 · n 550 · Phase 3 · primary NCT02826603
  • 54.2% vs 1.5% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 59.2% vs 1.2% 300 mg · wk 12 · n 245 · Phase 3 · secondary NCT01365455
  • 77.2% vs 1.5% 300 mg · wk 12 · n 272 · Phase 3 · secondary NCT03066609
  • 41.9% vs 1.5% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578
  • 39.1% vs 1.2% 150 mg · wk 12 · n 243 · Phase 3 · secondary NCT01365455
  • 62.5% vs 1.5% 150 mg · wk 12 · n 136 · Phase 3 · secondary NCT03066609
  • 75.6% vs 5% 300 mg · wk 12 · n 41 · Phase 3 · secondary NCT03589885
  • 47.1% vs 0% wk 12 · n 51 · Phase 3 · secondary NCT02267135
  • 66.7% vs 1.4% 2 mL PFS · wk 12 · n 72 · Phase 3 · secondary NCT02748863
  • 72.5% vs 2.4% low dose · wk 12 · n 40 · Phase 3 · secondary NCT02471144
  • 67.5% vs 2.4% high dose · wk 12 · n 40 · Phase 3 · secondary NCT02471144
  • 76.9% vs 54.2% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 68.6% vs 8.4% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 63.8% vs 2.1% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 46.7% vs 1.1% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 32.4% vs 0% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 17.1% vs 0% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 2.9% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 1.9% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 53.7% vs 0% 300 mg · wk 12 · n 54 · Phase 4 · primary NCT03055494
  • 73.9% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701
vunakizumab
—Trial running · NCT06833307

PASI 100

secukinumab
23.5% vs 0%+23.5 vs placebowk 12 · n 51NCT02267135
13 other results
  • 38.9% vs 0% 2 mL PFS · wk 12 · n 72 · Phase 3 · secondary NCT02748863
  • 36.6% vs 0% 2 x 1 mL PFS · wk 12 · n 71 · Phase 3 · secondary NCT02748863
  • 45.5% vs 26.6% 300 mg · wk 16 · n 550 · Phase 3 · secondary NCT02826603
  • 38.2% vs 20.1% 300 mg · wk 12 · n 550 · Phase 3 · secondary NCT02826603
  • 37.1% vs 0% wk 16 · n 105 · Phase 3 · secondary NCT02474082
  • 28.6% vs 0% wk 12 · n 105 · Phase 3 · secondary NCT02474082
  • 15.2% vs 0% wk 8 · n 105 · Phase 3 · secondary NCT02474082
  • 7.6% vs 0% wk 6 · n 105 · Phase 3 · secondary NCT02474082
  • 3.8% vs 0% wk 4 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 3 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 2 · n 105 · Phase 3 · secondary NCT02474082
  • 0% vs 0% wk 1 · n 105 · Phase 3 · secondary NCT02474082
  • 37% vs 0% wk 12 · n 46 · Phase 4 · secondary NCT02690701
vunakizumab
—Trial running · NCT06833307

sPGA 0/1

secukinumab
62.5% vs 2.8%+59.7 vs placebo300mg · wk 12 · n 323NCT01358578
3 other results
  • 51.1% vs 2.8% 150mg · wk 12 · n 327 · Phase 3 · primary NCT01358578
  • 62.5% vs 27.2% 300mg · wk 12 · n 323 · Phase 3 · secondary NCT01358578
  • 51.1% vs 27.2% 150mg · wk 12 · n 327 · Phase 3 · secondary NCT01358578
vunakizumab
—Trial running · NCT06833307

DLQI, change

secukinumab
-13.2 vs -2.0−11.2 vs placebo300 mg · wk 12 · n 41NCT03589885
1 other result
  • -9.4 vs -0.5 wk 12 · n 46 · Phase 4 · secondary NCT02690701
vunakizumab
—Trial running · NCT06833307
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

vunakizumab
Week 12 co-primary endpoints, vunakizumab 240 mg vs placebo (690 randomized 2:1): PASI 90 76.8% vs 0.9%; sPGA 0/1 71.8% vs 0.4%; both two-sided P < .0001 (Yan et al., J Am Acad Dermatol 2025). NCT04839016 · Phase 3 · design grade: strong · publication or press release
PASI 75 at week 12: 56.8% (40 mg), 65.8% (80 mg), 81.6% (160 mg), and 86.5% (240 mg) vs 5.4% placebo; P < .001 for all NCT03463187 · Phase 1/2 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. secukinumab: 4 of 4 rows · vunakizumab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricsecukinumab
Dropout rate
4.6%300mga
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
show 95 more results
—300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
3.7%150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
2.9%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
6.1%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
5.1%300 mg
NCT01555125 · Phase 3
—300 mg
NCT01555125 · Phase 3
1.7%150 mg
NCT01555125 · Phase 3
—150 mg
NCT01555125 · Phase 3
0%300 mg
NCT01636687 · Phase 3
—300 mg
NCT01636687 · Phase 3
4.9%150 mg
NCT01636687 · Phase 3
—150 mg
NCT01636687 · Phase 3
—300 mg
NCT02267135 · Phase 3
2%Secukinumab
NCT02267135 · Phase 3
—300 mg (2x1mL PFS)
NCT02748863 · Phase 3
—300 mg (2mL PFS)
NCT02748863 · Phase 3
0%2 mL PFS
NCT02748863 · Phase 3
—2 mL PFS
NCT02748863 · Phase 3
2.8%2 x 1 mL PFS
NCT02748863 · Phase 3
—2 x 1 mL PFS
NCT02748863 · Phase 3
—300 mg
NCT03589885 · Phase 3
0%
NCT04717466 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
18.5%300 mg
NCT03055494 · Phase 4 · registry result, not featured evidence
13.3%
NCT02592018 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02690701 · Phase 4 · registry result, not featured evidence
4.3%Secukinumab
NCT02690701 · Phase 4 · registry result, not featured evidence
0%300 mg
NCT02547714 · Phase 4 · registry result, not featured evidence
—Entire Period - Secukinumab (AIN45
NCT02547714 · Phase 4 · registry result, not featured evidence
—Induction Period - Secukinumab (AI
NCT02547714 · Phase 4 · registry result, not featured evidence
14.3%AIN457 High Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
26.2%AIN457 Low Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
10.3%300 mg every 2 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
13.3%300 mg every 4 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
9.7%300 mg every 4 weeks (up-titration)
NCT03504852 · Phase 3 · registry result, not featured evidence
—300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
0.7%300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
1.5%150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
11.1%300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
4.7%300 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
13%150 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
7.7%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
7%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
19%300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
18.8%150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 1
NCT02409667 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 2
NCT02409667 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 3
NCT02409667 · Phase 3 · registry result, not featured evidence
25%300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
48.5%300 mg open-label
NCT01640951 · Phase 3 · registry result, not featured evidence
78.3%300 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
16.1%300 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
20%150 mg fixed interval then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
13.7%150 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
81.8%150 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
59.7%150 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02595970 · Phase 3 · registry result, not featured evidence
16.7%Single Arm Secukinumab
NCT02595970 · Phase 3 · registry result, not featured evidence
1.5%300 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
6%150 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
7.2%300 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
7.4%150 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
3%300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—
NCT02362789 · Phase 3 · registry result, not featured evidence
10.1%300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
11.2%150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
15.1%300 mg
NCT02074982 · Phase 3 · registry result, not featured evidence
5.7%
NCT02474082 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
1.2%300mga
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
show 95 more results
—300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
0.6%150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
1.2%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
2%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
1.7%300 mg
NCT01555125 · Phase 3
—300 mg
NCT01555125 · Phase 3
0%150 mg
NCT01555125 · Phase 3
—150 mg
NCT01555125 · Phase 3
0%300 mg
NCT01636687 · Phase 3
—300 mg
NCT01636687 · Phase 3
1.6%150 mg
NCT01636687 · Phase 3
—150 mg
NCT01636687 · Phase 3
—300 mg
NCT02267135 · Phase 3
—Secukinumab
NCT02267135 · Phase 3
—300 mg (2x1mL PFS)
NCT02748863 · Phase 3
—300 mg (2mL PFS)
NCT02748863 · Phase 3
0%2 mL PFS
NCT02748863 · Phase 3
—2 mL PFS
NCT02748863 · Phase 3
1.4%2 x 1 mL PFS
NCT02748863 · Phase 3
—2 x 1 mL PFS
NCT02748863 · Phase 3
—300 mg
NCT03589885 · Phase 3
—
NCT04717466 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
—300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
0%300 mg
NCT03055494 · Phase 4 · registry result, not featured evidence
6.7%
NCT02592018 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02690701 · Phase 4 · registry result, not featured evidence
4.3%Secukinumab
NCT02690701 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02547714 · Phase 4 · registry result, not featured evidence
—Entire Period - Secukinumab (AIN45
NCT02547714 · Phase 4 · registry result, not featured evidence
—Induction Period - Secukinumab (AI
NCT02547714 · Phase 4 · registry result, not featured evidence
4.8%AIN457 High Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
2.4%AIN457 Low Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
2.4%300 mg every 2 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
5.9%300 mg every 4 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
6.5%300 mg every 4 weeks (up-titration)
NCT03504852 · Phase 3 · registry result, not featured evidence
—300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
0.7%300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
1.5%150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
3.1%300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
0.6%300 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
1%150 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
3.7%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
3.8%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
10.1%300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
7.5%150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 1
NCT02409667 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 2
NCT02409667 · Phase 3 · registry result, not featured evidence
—Treatment Period 2: Group 3
NCT02409667 · Phase 3 · registry result, not featured evidence
6%300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
9.1%300 mg open-label
NCT01640951 · Phase 3 · registry result, not featured evidence
18.3%300 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
0.9%300 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
4%150 mg fixed interval then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
1.1%150 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
10.9%150 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
10.4%150 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02595970 · Phase 3 · registry result, not featured evidence
4.2%Single Arm Secukinumab
NCT02595970 · Phase 3 · registry result, not featured evidence
0%300 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
3%150 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
1.4%300 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
1.5%150 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
1%300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—
NCT02362789 · Phase 3 · registry result, not featured evidence
2.5%300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
4.3%150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
4.5%300 mg
NCT02074982 · Phase 3 · registry result, not featured evidence
1.9%
NCT02474082 · Phase 3 · registry result, not featured evidence
Serious AEs
—300mga
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
show 95 more results
6.4%300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
1.2%300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
5.5%150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
2.1%150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
6.9%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
5.4%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
2.1%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
2.4%300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
6.1%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
5.4%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
1.7%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
1.6%150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
—300 mg
NCT01555125 · Phase 3
5.1%300 mg
NCT01555125 · Phase 3
—150 mg
NCT01555125 · Phase 3
1.7%150 mg
NCT01555125 · Phase 3
—300 mg
NCT01636687 · Phase 3
1.7%300 mg
NCT01636687 · Phase 3
—150 mg
NCT01636687 · Phase 3
4.9%150 mg
NCT01636687 · Phase 3
0%300 mg
NCT02267135 · Phase 3
—Secukinumab
NCT02267135 · Phase 3
1.4%300 mg (2x1mL PFS)
NCT02748863 · Phase 3
0%300 mg (2mL PFS)
NCT02748863 · Phase 3
—2 mL PFS
NCT02748863 · Phase 3
—2 mL PFS
NCT02748863 · Phase 3
—2 x 1 mL PFS
NCT02748863 · Phase 3
—2 x 1 mL PFS
NCT02748863 · Phase 3
2.4%300 mg
NCT03589885 · Phase 3
10%
NCT04717466 · Phase 4 · registry result, not featured evidence
5.4%300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
0%300 mg
NCT03020199 · Phase 4 · registry result, not featured evidence
1.9%300 mg
NCT03055494 · Phase 4 · registry result, not featured evidence
6.7%
NCT02592018 · Phase 4 · registry result, not featured evidence
10.9%300 mg
NCT02690701 · Phase 4 · registry result, not featured evidence
—Secukinumab
NCT02690701 · Phase 4 · registry result, not featured evidence
—300 mg
NCT02547714 · Phase 4 · registry result, not featured evidence
0%Entire Period - Secukinumab (AIN45
NCT02547714 · Phase 4 · registry result, not featured evidence
0%Induction Period - Secukinumab (AI
NCT02547714 · Phase 4 · registry result, not featured evidence
4.8%AIN457 High Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
9.5%AIN457 Low Dose
NCT03668613 · Phase 3 · registry result, not featured evidence
8.5%300 mg every 2 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
13.4%300 mg every 4 weeks
NCT03504852 · Phase 3 · registry result, not featured evidence
12.9%300 mg every 4 weeks (up-titration)
NCT03504852 · Phase 3 · registry result, not featured evidence
3.3%300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
3.7%150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence
5.3%300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01544595 · Phase 3 · registry result, not featured evidence
8.5%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
5.4%300 mg
NCT02394561 · Phase 3 · registry result, not featured evidence
—300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
16.5%300 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
—150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
11.3%150 mg
NCT02008890 · Phase 3 · registry result, not featured evidence
3.9%Treatment Period 2: Group 1
NCT02409667 · Phase 3 · registry result, not featured evidence
3.8%Treatment Period 2: Group 2
NCT02409667 · Phase 3 · registry result, not featured evidence
3.5%Treatment Period 2: Group 3
NCT02409667 · Phase 3 · registry result, not featured evidence
—300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—300 mg open-label
NCT01640951 · Phase 3 · registry result, not featured evidence
—300 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
—300 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—150 mg fixed interval then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—150 mg as needed then 300 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
—150 mg as needed
NCT01640951 · Phase 3 · registry result, not featured evidence
—150 mg fixed interval
NCT01640951 · Phase 3 · registry result, not featured evidence
10.8%300 mg
NCT02595970 · Phase 3 · registry result, not featured evidence
—Single Arm Secukinumab
NCT02595970 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
—150 mg
NCT01807520 · Phase 3 · registry result, not featured evidence · pooled
—300 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01806597 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
2.5%300 mg s.c. (2-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
4.9%300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
—300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
4.1%300 mg s.c. (4-weekly)
NCT02474069 · Phase 3 · registry result, not featured evidence
4.8%
NCT02362789 · Phase 3 · registry result, not featured evidence
—300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
13.4%300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
—150 mg - 300 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
12.2%150 mg
NCT01961609 · Phase 3 · registry result, not featured evidence
12.2%300 mg
NCT02074982 · Phase 3 · registry result, not featured evidence
3.8%
NCT02474082 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
300mga
nasopharyngitis 27.9% (placebo 8%)
headache 14.4% (placebo 7.3%)
diarrhoea 10.4% (placebo 2.1%)
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
show 51 more results
300mg
nasopharyngitis 10.7% (placebo 8%)
headache 9.2% (placebo 7.3%)
diarrhoea 5.2% (placebo 2.1%)
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
150mg
nasopharyngitis 25.1% (placebo 8%)
headache 10.4% (placebo 7.3%)
diarrhoea 9.2% (placebo 2.1%)
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
150mg
nasopharyngitis 13.5% (placebo 8%)
headache 4.9% (placebo 7.3%)
arthralgia 4.3% (placebo 3.1%)
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
300 mg
nasopharyngitis 18.4% (placebo 8.1%)
upper respiratory tract infection 10.6% (placebo 0.8%)
headache 9% (placebo 4%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
300 mg
nasopharyngitis 16.3% (placebo 8.1%)
upper respiratory tract infection 9.2% (placebo 0.8%)
headache 8.6% (placebo 4%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
300 mg
arthralgia 2.1% (placebo 3.2%)
blood creatinine increased 2.1% (placebo 0.4%)
eczema 2.1% (placebo 0%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
300 mg
nasopharyngitis 9% (placebo 8.1%)
headache 4.9% (placebo 4%)
pruritus 4.5% (placebo 2.4%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
150 mg
nasopharyngitis 21.6% (placebo 8.1%)
upper respiratory tract infection 11.4% (placebo 0.8%)
headache 7.8% (placebo 4%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
150 mg
nasopharyngitis 19.5% (placebo 8.1%)
upper respiratory tract infection 10.2% (placebo 0.8%)
headache 6.8% (placebo 4%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
150 mg
psoriasis 3.4% (placebo 3.2%)
psoriatic arthropathy 3.4% (placebo 1.6%)
influenza 1.7% (placebo 1.2%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
150 mg
nasopharyngitis 9.4% (placebo 8.1%)
headache 5.3% (placebo 4%)
oropharyngeal pain 4.1% (placebo 1.2%)
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
300 mg
diarrhoea 8.5% (placebo 1.7%)
back pain 5.1% (placebo 0%)
nasopharyngitis 5.1% (placebo 8.5%)
NCT01555125 · Phase 3
150 mg
headache 6.8% (placebo 6.8%)
diarrhoea 5.1% (placebo 1.7%)
nasopharyngitis 5.1% (placebo 8.5%)
NCT01555125 · Phase 3
300 mg
nasopharyngitis 31.7% (placebo 14.8%)
pruritus 6.7% (placebo 3.3%)
cough 5% (placebo 3.3%)
NCT01636687 · Phase 3
150 mg
nasopharyngitis 23% (placebo 14.8%)
headache 8.2% (placebo 4.9%)
hypertension 4.9% (placebo 6.6%)
NCT01636687 · Phase 3
300 mg
dermatitis contact 5.9% (placebo 3.9%)
nasopharyngitis 5.9% (placebo 2%)
diarrhoea 3.9% (placebo 3.9%)
NCT02267135 · Phase 3
300 mg (2x1mL PFS)
nasopharyngitis 11.3% (placebo 11.3%)
headache 8.5% (placebo 4.2%)
back pain 4.2% (placebo 2.8%)
NCT02748863 · Phase 3
300 mg (2mL PFS)
nasopharyngitis 9.7% (placebo 11.3%)
headache 8.3% (placebo 4.2%)
pruritus 6.9% (placebo 4.2%)
NCT02748863 · Phase 3
300 mg
nasopharyngitis 14.6% (placebo 0%)
hypertension 9.8% (placebo 0%)
influenza like illness 7.3% (placebo 2.5%)
NCT03589885 · Phase 3
itch 20%
bruising 10%
felt cramped 10%
NCT04717466 · Phase 4 · registry result, not featured evidence
300 mg
headache 9.8%
nasopharyngitis 9.8%
upper respiratory tract infection 7.1%
NCT03020199 · Phase 4 · registry result, not featured evidence
300 mg
arthralgia 5.7%
nasopharyngitis 3.4%
headache 1.1%
NCT03020199 · Phase 4 · registry result, not featured evidence
300 mg
nasopharyngitis 18.5%
upper respiratory tract infection 13%
back pain 7.4%
NCT03055494 · Phase 4 · registry result, not featured evidence
upper respiratory infection 60%
cough 20%
diarrhea 13.3%
NCT02592018 · Phase 4 · registry result, not featured evidence
300 mg
nasopharyngitis 19.6%
upper respiratory tract infection 13%
arthralgia 10.9%
NCT02690701 · Phase 4 · registry result, not featured evidence
nasopharyngitis 20.6%
dermatitis contact 5.9%
hypertension 5.9%
NCT02547714 · Phase 4 · registry result, not featured evidence
nasopharyngitis 11.8%
alopecia 2.9%
dermatitis contact 2.9%
NCT02547714 · Phase 4 · registry result, not featured evidence
covid-19 21.4%
nasopharyngitis 16.7%
viral upper respiratory tract infection 16.7%
NCT03668613 · Phase 3 · registry result, not featured evidence
nasopharyngitis 31%
covid-19 26.2%
acne 16.7%
NCT03668613 · Phase 3 · registry result, not featured evidence
300 mg every 2 weeks
nasopharyngitis 19.4%
upper respiratory tract infection 7.3%
headache 6.7%
NCT03504852 · Phase 3 · registry result, not featured evidence
300 mg every 4 weeks
nasopharyngitis 16.4%
upper respiratory tract infection 6.7%
oropharyngeal pain 5.2%
NCT03504852 · Phase 3 · registry result, not featured evidence
300 mg every 4 weeks (up-titration)
nasopharyngitis 16.1%
intertrigo 9.7%
neutrophil count decreased 9.7%
NCT03504852 · Phase 3 · registry result, not featured evidence
300 mg
upper respiratory tract infection 24.6% (placebo 9.6%)
hyperuricaemia 20.6% (placebo 12.6%)
nasopharyngitis 16.2% (placebo 3.7%)
NCT03066609 · Phase 3 · registry result, not featured evidence
150 mg
upper respiratory tract infection 30.1% (placebo 9.6%)
hyperuricaemia 18.4% (placebo 12.6%)
influenza 12.5% (placebo 3%)
NCT03066609 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 10%
upper respiratory tract infection 8.9%
diarrhoea 4.7%
NCT02826603 · Phase 3 · registry result, not featured evidence
300 mg
hypertension 4.1%
pruritus 1.6%
NCT02394561 · Phase 3 · registry result, not featured evidence
300 mg
pruritus 6.5%
hypertension 5.9%
NCT02394561 · Phase 3 · registry result, not featured evidence
300 mg
viral upper respiratory tract infection 39.2% (placebo 15.4%)
pustular psoriasis 20.3% (placebo 5.1%)
headache 15.2% (placebo 12.8%)
NCT02008890 · Phase 3 · registry result, not featured evidence
150 mg
pustular psoriasis 23.8% (placebo 5.1%)
viral upper respiratory tract infection 21.3% (placebo 15.4%)
headache 8.8% (placebo 12.8%)
NCT02008890 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 14.6% (placebo 23.7%)
headache 4.8% (placebo 1.1%)
back pain 2.8% (placebo 1.1%)
NCT02409667 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 14.4% (placebo 23.7%)
back pain 4.2% (placebo 1.1%)
headache 4.1% (placebo 1.1%)
NCT02409667 · Phase 3 · registry result, not featured evidence
viral upper respiratory tract infection 20.2% (placebo 23.7%)
psoriasis 9.6% (placebo 8.6%)
upper respiratory tract infection 6.1% (placebo 5.4%)
NCT02409667 · Phase 3 · registry result, not featured evidence
300 mg
back pain 10.8%
nasopharyngitis 10.8%
diarrhoea 10%
NCT02595970 · Phase 3 · registry result, not featured evidence
300 mg s.c. (2-weekly)
nasopharyngitis 16.6%
headache 3.1%
hypertension 2.5%
NCT02474069 · Phase 3 · registry result, not featured evidence
300 mg s.c. (4-weekly)
nasopharyngitis 14.2%
headache 3.1%
arthralgia 2.5%
NCT02474069 · Phase 3 · registry result, not featured evidence
300 mg s.c. (4-weekly)
nasopharyngitis 21.8%
headache 7.8%
diarrhoea 4.4%
NCT02474069 · Phase 3 · registry result, not featured evidence
nasopharyngitis 28.6% (placebo 28.9%)
headache 7.1% (placebo 2.6%)
hypertension 4.8% (placebo 5.3%)
NCT02362789 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 29.1%
oropharyngeal pain 16.2%
headache 15.6%
NCT01961609 · Phase 3 · registry result, not featured evidence
150 mg
headache 23.5%
nasopharyngitis 23.5%
psoriasis 13%
NCT01961609 · Phase 3 · registry result, not featured evidence
300 mg
nasopharyngitis 28.7%
headache 14.9%
upper respiratory tract infection 12.5%
NCT02074982 · Phase 3 · registry result, not featured evidence
nasopharyngitis 51.4%
headache 14.3%
diarrhoea 6.7%
NCT02474082 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 78 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

secukinumab

PASI 75 77.1% (n=323) vs 4.9% (n=324) placebo @ 12wk300mg
responder rate · % of participants
Induction
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 249 participants achieving goal as posted
show 27 more results
77.1% (n=323) vs 44% (n=323) Etanercept @ 12wk*300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 249 participant who acheived goal as posted
81.6% (n=245) vs 4.5% (n=246) placebo @ 12wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
75.9% (n=58) vs 0% (n=59) placebo @ 12wk300 mg
NCT01555125 · Phase 3
95.1% (n=41) vs 10% (n=40) placebo @ 12wk*300 mg
NCT03589885 · Phase 3 · converted to % from 39 Participants as posted
93.4% (n=272) vs 4.4% (n=135) placebo @ 12wk*300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence · converted to % from 254 Participants as posted
88% (n=550) vs 74.1% (n=552) Ustekinumab @ 12wk*300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence · converted to % from 484 Participants as posted
40.2% (n=550) vs 16.3% (n=552) Ustekinumab @ 4wk*300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence · converted to % from 221 Participants as posted
92% (n=550) vs 79.9% (n=552) Ustekinumab @ 16wk*300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence · converted to % from 506 Participants as posted
49.7% (n=334) vs 20.6% (n=335) Ustekinumab @ 4wk300 mg
NCT02074982 · Phase 3 · registry result, not featured evidence
67% (n=327) vs 4.9% (n=324) placebo @ 12wk*150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 219 participants achieving goal as posted
67% (n=327) vs 44% (n=323) Etanercept @ 12wk*150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 219 participant who acheived goal as posted
71.6% (n=243) vs 4.5% (n=246) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
69.5% (n=59) vs 0% (n=59) placebo @ 12wk150 mg
NCT01555125 · Phase 3
82.4% (n=136) vs 4.4% (n=135) placebo @ 12wk*150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence · converted to % from 112 Participants as posted
64.7% (n=51) vs 2% (n=51) placebo @ 12wk
NCT02267135 · Phase 3
88.9% (n=72) vs 1.4% (n=71) placebo @ 12wk*2 mL PFS
NCT02748863 · Phase 3 · converted to % from 64 participants as posted
80% (n=40) vs 14.6% (n=41) placebo @ 12wk*low dose
NCT02471144 · Phase 3 · converted to % from 32 Participants as posted
77.5% (n=40) vs 14.6% (n=41) placebo @ 12wk*high dose
NCT02471144 · Phase 3 · converted to % from 31 Participants as posted
84.8% (n=46) vs 0% (n=45) placebo @ 12wk
NCT02690701 · Phase 4 · registry result, not featured evidence
0% (n=105) vs 0% (n=95) Fumaric Acid @ 1wk
NCT02474082 · Phase 3 · registry result, not featured evidence
5.7% (n=105) vs 0% (n=95) Fumaric Acid @ 2wk
NCT02474082 · Phase 3 · registry result, not featured evidence
24.8% (n=105) vs 0% (n=95) Fumaric Acid @ 3wk
NCT02474082 · Phase 3 · registry result, not featured evidence
47.6% (n=105) vs 1.1% (n=95) Fumaric Acid @ 4wk
NCT02474082 · Phase 3 · registry result, not featured evidence
69.5% (n=105) vs 2.1% (n=95) Fumaric Acid @ 6wk
NCT02474082 · Phase 3 · registry result, not featured evidence
80% (n=105) vs 8.4% (n=95) Fumaric Acid @ 8wk
NCT02474082 · Phase 3 · registry result, not featured evidence
87.6% (n=105) vs 21.1% (n=95) Fumaric Acid @ 12wk
NCT02474082 · Phase 3 · registry result, not featured evidence
88.6% (n=105) vs 27.4% (n=95) Fumaric Acid @ 16wk
NCT02474082 · Phase 3 · registry result, not featured evidence
sPGA 0/1 62.5% (n=323) vs 2.8% (n=324) placebo @ 12wk300mg
responder rate · % of participants
Induction
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 202 participants acheiving goal as posted
show 3 more results
62.5% (n=323) vs 27.2% (n=323) Etanercept @ 12wk*300mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 202 participant acheiving goal as posted
51.1% (n=327) vs 2.8% (n=324) placebo @ 12wk*150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 167 participants acheiving goal as posted
51.1% (n=327) vs 27.2% (n=323) Etanercept @ 12wk*150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 167 participant acheiving goal as posted
PASI 90 54.2% (n=323) vs 1.5% (n=324) placebo @ 12wk300mg
responder rate · % of participants
Induction
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 175 participant who acheived goal as posted
show 23 more results
59.2% (n=245) vs 1.2% (n=246) placebo @ 12wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
75.6% (n=41) vs 5% (n=40) placebo @ 12wk*300 mg
NCT03589885 · Phase 3 · converted to % from 31 Participants as posted
53.7% (n=54) vs 0% (n=28) placebo @ 12wk*300 mg
NCT03055494 · Phase 4 · registry result, not featured evidence · converted to % from 29 Participants as posted
77.2% (n=272) vs 1.5% (n=135) placebo @ 12wk*300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence · converted to % from 210 Participants as posted
66.5% (n=550) vs 48% (n=552) Ustekinumab @ 12wk*300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence · converted to % from 366 Participants as posted
76.9% (n=550) vs 54.2% (n=552) Ustekinumab @ 16wk*300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence · converted to % from 423 Participants as posted
79% (n=334) vs 57.3% (n=335) Ustekinumab @ 16wk300 mg
NCT02074982 · Phase 3 · registry result, not featured evidence
41.9% (n=327) vs 1.5% (n=324) placebo @ 12wk*150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 137 participant who acheived goal as posted
39.1% (n=243) vs 1.2% (n=246) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
62.5% (n=136) vs 1.5% (n=135) placebo @ 12wk*150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence · converted to % from 85 Participants as posted
47.1% (n=51) vs 0% (n=51) placebo @ 12wk
NCT02267135 · Phase 3
66.7% (n=72) vs 1.4% (n=71) placebo @ 12wk*2 mL PFS
NCT02748863 · Phase 3 · converted to % from 48 participants as posted
72.5% (n=40) vs 2.4% (n=41) placebo @ 12wk*low dose
NCT02471144 · Phase 3 · converted to % from 29 Participants as posted
67.5% (n=40) vs 2.4% (n=41) placebo @ 12wk*high dose
NCT02471144 · Phase 3 · converted to % from 27 Participants as posted
73.9% (n=46) vs 0% (n=45) placebo @ 12wk
NCT02690701 · Phase 4 · registry result, not featured evidence
0% (n=105) vs 0% (n=95) Fumaric Acid @ 1wk
NCT02474082 · Phase 3 · registry result, not featured evidence
1.9% (n=105) vs 0% (n=95) Fumaric Acid @ 2wk
NCT02474082 · Phase 3 · registry result, not featured evidence
2.9% (n=105) vs 0% (n=95) Fumaric Acid @ 3wk
NCT02474082 · Phase 3 · registry result, not featured evidence
17.1% (n=105) vs 0% (n=95) Fumaric Acid @ 4wk
NCT02474082 · Phase 3 · registry result, not featured evidence
32.4% (n=105) vs 0% (n=95) Fumaric Acid @ 6wk
NCT02474082 · Phase 3 · registry result, not featured evidence
46.7% (n=105) vs 1.1% (n=95) Fumaric Acid @ 8wk
NCT02474082 · Phase 3 · registry result, not featured evidence
63.8% (n=105) vs 2.1% (n=95) Fumaric Acid @ 12wk
NCT02474082 · Phase 3 · registry result, not featured evidence
68.6% (n=105) vs 8.4% (n=95) Fumaric Acid @ 16wk
NCT02474082 · Phase 3 · registry result, not featured evidence
PASI 75 Response Maintenance 84.3% (n=249) vs 72.5% (n=142) Etanercept @ 52wk300mg
event count · % of participants
Maintenance
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 210 participants who reached goal as posted
show 1 more result
82.2% (n=219) vs 72.5% (n=142) Etanercept @ 52wk*150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 180 participants who reached goal as posted
sPGA 0 1 Response Maintenance 79.7% (n=202) vs 56.8% (n=88) Etanercept @ 52wk300mg
event count · % of participants
Maintenance
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 161 participants who reached goal as posted
show 1 more result
67.7% (n=167) vs 56.8% (n=88) Etanercept @ 52wk*150mg
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to % from 113 participants who reached goal as posted
Scaling -4.93 vs -0.42 placebo score @ 12wk300mg
absolute change · score
Induction
Scaling
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
show 3 more results
-4.93 vs -3.74 Etanercept score @ 12wk300mg
Scaling
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
-4.89 vs -0.42 placebo score @ 12wk150mg
Scaling
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
-4.89 vs -3.74 Etanercept score @ 12wk150mg
Scaling
NCT01358578 · Phase 3 · monotherapy · Psoriasis · phase 3
IGA 0/1 65.3% (n=245) vs 2.4% (n=246) placebo @ 12wk300 mg
responder rate · % of participants
Induction
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 22 more results
69% (n=58) vs 0% (n=59) placebo @ 12wk300 mg
NCT01555125 · Phase 3
75.6% (n=41) vs 7.5% (n=40) placebo @ 12wk*300 mg
NCT03589885 · Phase 3 · converted to % from 31 Participants as posted
78.7% (n=272) vs 3% (n=135) placebo @ 12wk*300 mg
NCT03066609 · Phase 3 · registry result, not featured evidence · converted to % from 214 Participants as posted
72.2% (n=550) vs 55.4% (n=552) Ustekinumab @ 12wk*300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence · converted to % from 397 Participants as posted
78.5% (n=550) vs 59.1% (n=552) Ustekinumab @ 16wk*300 mg
NCT02826603 · Phase 3 · registry result, not featured evidence · converted to % from 432 Participants as posted
51.2% (n=244) vs 2.4% (n=246) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
52.5% (n=59) vs 0% (n=59) placebo @ 12wk150 mg
NCT01555125 · Phase 3
67.6% (n=136) vs 3% (n=135) placebo @ 12wk*150 mg
NCT03066609 · Phase 3 · registry result, not featured evidence · converted to % from 92 Participants as posted
56.9% (n=51) vs 5.9% (n=51) placebo @ 12wk
NCT02267135 · Phase 3
52.9% (n=51) vs 3.9% (n=51) placebo @ 12wk
NCT02267135 · Phase 3
76.4% (n=72) vs 1.4% (n=71) placebo @ 12wk*2 mL PFS
NCT02748863 · Phase 3 · converted to % from 55 participants as posted
70% (n=40) vs 5% (n=40) placebo @ 12wk*low dose
NCT02471144 · Phase 3 · converted to % from 28 Participants as posted
60% (n=40) vs 5% (n=40) placebo @ 12wk*high dose
NCT02471144 · Phase 3 · converted to % from 24 Participants as posted
78.3% (n=46) vs 0% (n=45) placebo @ 12wk
NCT02690701 · Phase 4 · registry result, not featured evidence
0% (n=105) vs 0% (n=95) Fumaric Acid @ 1wk
NCT02474082 · Phase 3 · registry result, not featured evidence
5.7% (n=105) vs 0% (n=95) Fumaric Acid @ 2wk
NCT02474082 · Phase 3 · registry result, not featured evidence
13.3% (n=105) vs 1.1% (n=95) Fumaric Acid @ 3wk
NCT02474082 · Phase 3 · registry result, not featured evidence
34.3% (n=105) vs 1.1% (n=95) Fumaric Acid @ 4wk
NCT02474082 · Phase 3 · registry result, not featured evidence
50.5% (n=105) vs 2.1% (n=95) Fumaric Acid @ 6wk
NCT02474082 · Phase 3 · registry result, not featured evidence
66.7% (n=105) vs 4.2% (n=95) Fumaric Acid @ 8wk
NCT02474082 · Phase 3 · registry result, not featured evidence
77.1% (n=105) vs 12.6% (n=95) Fumaric Acid @ 12wk
NCT02474082 · Phase 3 · registry result, not featured evidence
80% (n=105) vs 14.7% (n=95) Fumaric Acid @ 16wk
NCT02474082 · Phase 3 · registry result, not featured evidence
PASI -17.5% (n=245) vs -3.7% (n=247) placebo @ 1wk300 mg
percent change · % of baseline
Induction
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 11 more results
-36.51% (n=245) vs -5.63% (n=247) placebo @ 2wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-51.59% (n=245) vs -8.62% (n=247) placebo @ 3wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-64.61% (n=245) vs -8.89% (n=247) placebo @ 4wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-82.98% (n=245) vs -8.15% (n=247) placebo @ 8wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-87.72% (n=245) vs -5.89% (n=247) placebo @ 12wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-12.08% (n=245) vs -3.7% (n=247) placebo @ 1wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-28.61% (n=245) vs -5.63% (n=247) placebo @ 2wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-42.79% (n=245) vs -8.62% (n=247) placebo @ 3wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-55.73% (n=245) vs -8.89% (n=247) placebo @ 4wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-76.35% (n=245) vs -8.15% (n=247) placebo @ 8wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-80.87% (n=245) vs -5.89% (n=247) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
PASI -89.55% (n=245) vs -63.1% (n=18) placebo @ 13wk300 mg
percent change · % of baseline
Maintenance
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 51 more results
-21.66% (n=105) vs -63.1% (n=18) placebo @ 13wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.83% (n=245) vs -68.74% (n=18) placebo @ 14wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-41.97% (n=105) vs -68.74% (n=18) placebo @ 14wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.4% (n=245) vs -67.15% (n=18) placebo @ 15wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-57.77% (n=105) vs -67.15% (n=18) placebo @ 15wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.37% (n=245) vs -73.38% (n=18) placebo @ 16wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-70.15% (n=105) vs -73.38% (n=18) placebo @ 16wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.86% (n=245) vs -80.57% (n=18) placebo @ 20wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.53% (n=105) vs -80.57% (n=18) placebo @ 20wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.83% (n=245) vs -78.06% (n=18) placebo @ 24wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.2% (n=105) vs -78.06% (n=18) placebo @ 24wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.15% (n=245) vs -79.55% (n=18) placebo @ 28wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.24% (n=105) vs -79.55% (n=18) placebo @ 28wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.9% (n=245) vs -75.94% (n=18) placebo @ 32wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.09% (n=105) vs -75.94% (n=18) placebo @ 32wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.04% (n=245) vs -78.37% (n=18) placebo @ 36wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.97% (n=105) vs -78.37% (n=18) placebo @ 36wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.62% (n=245) vs -78.32% (n=18) placebo @ 40wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.76% (n=105) vs -78.32% (n=18) placebo @ 40wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-88.97% (n=245) vs -79.96% (n=18) placebo @ 44wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.37% (n=105) vs -79.96% (n=18) placebo @ 44wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.35% (n=245) vs -79.54% (n=18) placebo @ 48wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-88.44% (n=105) vs -79.54% (n=18) placebo @ 48wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-88.42% (n=245) vs -79.64% (n=18) placebo @ 52wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-87.66% (n=105) vs -79.64% (n=18) placebo @ 52wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.12% (n=245) vs -63.1% (n=18) placebo @ 13wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-21.03% (n=108) vs -63.1% (n=18) placebo @ 13wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.47% (n=245) vs -68.74% (n=18) placebo @ 14wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-39.2% (n=108) vs -68.74% (n=18) placebo @ 14wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.67% (n=245) vs -67.15% (n=18) placebo @ 15wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-51.78% (n=108) vs -67.15% (n=18) placebo @ 15wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-85.2% (n=245) vs -73.38% (n=18) placebo @ 16wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-62.19% (n=108) vs -73.38% (n=18) placebo @ 16wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-85.75% (n=245) vs -80.57% (n=18) placebo @ 20wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-77.75% (n=108) vs -80.57% (n=18) placebo @ 20wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-85.46% (n=245) vs -78.06% (n=18) placebo @ 24wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.19% (n=108) vs -78.06% (n=18) placebo @ 24wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.72% (n=245) vs -79.55% (n=18) placebo @ 28wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.07% (n=108) vs -79.55% (n=18) placebo @ 28wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.98% (n=245) vs -75.94% (n=18) placebo @ 32wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-84.26% (n=108) vs -75.94% (n=18) placebo @ 32wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-81.87% (n=245) vs -78.37% (n=18) placebo @ 36wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.68% (n=108) vs -78.37% (n=18) placebo @ 36wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-81.37% (n=245) vs -78.32% (n=18) placebo @ 40wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-82.83% (n=108) vs -78.32% (n=18) placebo @ 40wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-80.81% (n=245) vs -79.96% (n=18) placebo @ 44wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.44% (n=108) vs -79.96% (n=18) placebo @ 44wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-79.78% (n=245) vs -79.54% (n=18) placebo @ 48wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.4% (n=108) vs -79.54% (n=18) placebo @ 48wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-79.74% (n=245) vs -79.64% (n=18) placebo @ 52wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-82.14% (n=108) vs -79.64% (n=18) placebo @ 52wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
Time to Response 1.87 vs NA placebo months @ 12wk300 mg
time to event · months
Induction
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to months from 57 days as posted
show 1 more result
1.87 vs NA placebo months @ 12wk*150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3 · converted to months from 57 days as posted
DLQI -62.5% (n=245) vs -5% (n=247) placebo @ 4wk300 mg
percent change · % of baseline
Induction
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 9 more results
-81.5% (n=245) vs -8.3% (n=247) placebo @ 8wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-86.4% (n=245) vs -9.1% (n=247) placebo @ 12wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-85% (n=53) vs -16.7% (n=54) placebo @ 12wk300 mg
NCT01555125 · Phase 3
-86.8% (n=55) vs -17.9% (n=55) placebo @ 12wk300 mg
NCT01636687 · Phase 3
-55% (n=245) vs -5% (n=247) placebo @ 4wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-73.1% (n=245) vs -8.3% (n=247) placebo @ 8wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-77.8% (n=245) vs -9.1% (n=247) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-78.6% (n=56) vs -16.7% (n=54) placebo @ 12wk150 mg
NCT01555125 · Phase 3
-83.3% (n=56) vs -17.9% (n=55) placebo @ 12wk150 mg
NCT01636687 · Phase 3
DLQI -86.4% (n=245) vs -58.3% (n=18) placebo @ 12wk300 mg
percent change · % of baseline
Maintenance
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
show 17 more results
-4.4% (n=105) vs -58.3% (n=18) placebo @ 12wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-89.6% (n=245) vs -76.6% (n=18) placebo @ 24wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.3% (n=105) vs -76.6% (n=18) placebo @ 24wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.7% (n=245) vs -77.9% (n=18) placebo @ 36wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90% (n=105) vs -77.9% (n=18) placebo @ 36wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-88.9% (n=245) vs -64.4% (n=18) placebo @ 52wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-88.9% (n=105) vs -64.4% (n=18) placebo @ 52wk300 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-91.2% (n=55) vs -53.7% (n=3) placebo @ 52wk300 mg
NCT01636687 · Phase 3
-77.8% (n=245) vs -58.3% (n=18) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-7.1% (n=108) vs -58.3% (n=18) placebo @ 12wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.3% (n=245) vs -76.6% (n=18) placebo @ 24wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-83.3% (n=108) vs -76.6% (n=18) placebo @ 24wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-78.6% (n=245) vs -77.9% (n=18) placebo @ 36wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-78.5% (n=108) vs -77.9% (n=18) placebo @ 36wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-76.5% (n=245) vs -64.4% (n=18) placebo @ 52wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-75% (n=108) vs -64.4% (n=18) placebo @ 52wk150 mg
NCT01365455 · Phase 3 · monotherapy · Psoriasis · phase 3
-90.9% (n=56) vs -53.7% (n=3) placebo @ 52wk150 mg
NCT01636687 · Phase 3

+ 167 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: secukinumab's landscape · vunakizumab's landscape